FOR IMMEDIATE RELEASE

HEALTH CANADA APPROVES REMODULIN™

Montreal, Canada, October 8, 2002 - Paladin Labs Inc. ("Paladin") (TSX: PLB), a Canadian specialty pharmaceutical company focused on marketing and selling urology, endocrinology and women's health products, today announced that the Therapeutic Products Directorate of Health Canada has accepted United Therapeutics Corporation's (Nasdaq: UTHR) New Drug Submission for Remodulin™ (treprostinil sodium) Injection.

There are currently only five patients across Canada on Remodulin™ therapy. Paladin is currently in discussions to transition the Canadian distribution responsibilities of Remodulin™ to United Therapeutics, who will also be responsible for pursuing provincial pricing approval for Remodulin™.

Paladin acquired the exclusive Canadian distribution rights for Remodulin™ from United Therapeutics in February 1999. Formerly referred to as UNIPROST™, Remodulin™ is indicated for the long-term sub-cutaneous treatment of pulmonary arterial hypertension in NYHA Class III and IV patients who do not respond adequately to conventional therapy. The United States Food and Drug Administration granted U.S. approval of Remodulin™ on May 21, 2002.

About Paladin Labs Inc:
Paladin Labs Inc., headquartered in Montreal, Quebec, is a rapidly growing pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's most profitable publicly traded pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Paladin Web Site at www.paladinlabs.com

This news release may contain forward-looking statements or predictions. These statements represent our judgement as of this date and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. Potential risks and uncertainties include, without limitation, those associated with product development, clinical trials, future revenues and profitability, and obtaining marketing approval.

For further information please contact:

Paladin Labs Inc.
Samira Sakhia, Chief Financial Officer
Tel: 514-340-5067
e-mail: info@paladin-labs.com
Web Site: www.paladinlabs.com

The Equicom Group Inc.
Bruce Wigle, Investor Relations
Tel: (416) 815-0700 ext.228
e-mail: bwigle@equicomgroup.com